Ipsen (IPSEY) said on Friday that its pivotal Phase II FALKON study evaluating fidrisertib in patients with fibrodysplasia ossificans progressiva (FOP) failed to meet its primary endpoint, prompting the company to close the trial.
The primary endpoint was the reduction of new heterotopic ossification, or abnormal bone formation in soft tissues, in patients with FOP, an extremely rare genetic disorder in which abnormal bone formation progressively replaces muscles and connective tissues.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.